Home » Personalized Medicine May Be Good for Patients But Bad for Drug Companies’ Bottom Line
Personalized Medicine May Be Good for Patients But Bad for Drug Companies’ Bottom Line
Personalized, targeted therapies led to Vertex’s Kalydeco breakthrough for cystic fibrosis patients and would allow drugmakers to conduct more concise, targeted clinical trials, says Forbes.
Forbes
Forbes
Upcoming Events
-
07May
-
14May
-
30May